Mounjaro Leads India's GLP-1 Market With ₹1,256 Crore Sales

Eli Lilly's diabetes and weight-loss medicine Mounjaro has become the top-selling GLP-1 drug in India, with sales reaching ₹1,256 crore in the 12 months ended August. According to Pharmarack's PharmaTrac data, the drug recorded a 502% increase in sales value during this period, driven by rising demand for GLP-1 therapies.

The overall GLP-1 market in India has expanded significantly, with unit sales growing 74% in August. The segment's value reached ₹2,333 crore for the year ended August, with injectable medicines accounting for nearly 86% of total sales. Mounjaro generated sales of around ₹112 crore in August alone, although its unit sales declined possibly due to patients shifting towards higher dosage levels and changes in vial usage patterns.

Injectable treatments have become the dominant category within the GLP-1 market, with sales of around ₹2,010 crore in August, compared to ₹348 crore a year earlier. Tirzepatide, the active ingredient in Mounjaro, held the largest share of the market at nearly 62%, while semaglutide accounted for around 34%. Dulaglutide and liraglutide contributed the remaining portion.

The growth of generic semaglutide medicines has also helped expand India's GLP-1 market by making treatments more affordable for a wider group of patients. However, original branded medicines have continued to maintain demand despite increased competition. Semaglutide injections have gained popularity, while oral semaglutide witnessed a slight decline in August, indicating a stronger preference among patients for injectable therapies.

Industry data suggests that the market may now be moving towards a more stable growth phase after the rapid expansion triggered by generic launches. Future growth is expected to depend on increasing awareness, bringing more eligible patients into treatment, and encouraging existing users to adopt newer injectable options.

The rise of Mounjaro and the GLP-1 market in India reflects the growing demand for effective diabetes and weight-loss treatments. As the market continues to evolve, it is likely that we will see increased competition and innovation in the development of new therapies.

In conclusion, Mounjaro's success in India's GLP-1 market is a significant milestone, and its impact will be closely watched by the pharmaceutical industry and healthcare professionals. The growth of the GLP-1 market in India is expected to continue, driven by increasing demand for effective treatments and the expansion of patient access to affordable therapies.

The Indian pharmaceutical market is a significant player in the global healthcare industry, and the success of drugs like Mounjaro is a testament to the country's growing importance in the development and distribution of medicines. As the market continues to grow and evolve, it is likely that we will see new opportunities and challenges emerge, shaping the future of healthcare in India and beyond.

The GLP-1 market in India is expected to continue its growth trajectory, driven by the increasing prevalence of diabetes and obesity, and the growing demand for effective treatments. The market's expansion will be influenced by factors such as patient awareness, healthcare infrastructure, and the availability of affordable therapies.

Overall, the success of Mounjaro in India's GLP-1 market is a significant development, and its impact will be felt across the pharmaceutical industry and healthcare sector. As the market continues to evolve, it is likely that we will see new innovations and opportunities emerge, shaping the future of healthcare in India and beyond.